BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

PR Pharmaceuticals, Inc. Announces Initiation Of A Phase I Study Of A New Potential Treatment For Pulmonary Arterial Hypertension


3/28/2006 11:02:40 AM

FORT COLLINS, Colo., March 27 /PRNewswire/ -- PR Pharmaceuticals, Inc. (PRP) announced today that healthy volunteers were dosed with PulmoLAR(TM) (2-methoxyestradiol - 2ME) in a Phase I clinical study. The double-blind, placebo-controlled clinical study is designed to assess the safety, tolerability and pharmacokinetics of a subcutaneous injection of PulmoLAR.

"Initiation of this Phase I clinical study for PulmoLAR is a significant milestone for our company and a pivotal step in the development of this important product which we hope leads to a novel treatment for pulmonary arterial hypertension (PAH)," said Steve Howe, PRP's Chairman and CEO. "Our executive team recognizes and appreciates the tremendous effort and dedication of our employees in the successes which have brought PulmoLAR to this stage of development."

Stevan P. Tofovic, M.D., Ph.D., Assistant Professor at the University of Pittsburgh School of Medicine and key investigator/inventor on the use of 2ME for PAH stated, "It is very gratifying to see our collaborative efforts with PRP come to fruition as PulmoLAR enters the clinical phase of development. We're optimistic that PulmoLAR may provide significant therapeutic benefits in the treatment of PAH, a devastating disease for which additional therapies are desperately needed."

About PulmoLAR

The active ingredient in PulmoLAR is 2ME. 2ME has multiple mechanisms of action, many of which are relevant to PAH. In vitro studies have demonstrated 2ME reduces endothelial cell production of endothelin-1 and increases synthesis of prostacyclin. 2ME is also a potent antiproliferative agent. PulmoLAR is PRP's proprietary sustained-release injectable formulation.

About PR Pharmaceuticals, Inc.

PRP is a biopharmaceutical company developing, manufacturing and commercializing bioactive compounds in its injectable sustained-release technologies. The Company has a significant intellectual property position in the encapsulation of large molecules such as proteins and peptides as well as encapsulation of classic small molecules into biodegradable microparticles. PRP is applying compelling and patented technology to create a diverse range of candidate pharmaceutical products to address unmet medical needs. For more information, please see www.prpharm.com

PulmoLAR(TM) is a trademark of PR Pharmaceuticals, Inc.

Media contact: Dr. Claude Piche (970) 484-5560

PR Pharmaceuticals, Inc.

CONTACT: Dr. Claude Piche, +1-970-484-5560, for PR Pharmaceuticals, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES